Advances in pharmacologyPub Date : 2026-01-01Epub Date: 2026-06-08DOI: 10.1016/bs.apha.2026.05.003
Saar I Gill
{"title":"In vivo transduction of CAR T cells: Pharmacological principles, delivery platforms, and the road to clinical translation.","authors":"Saar I Gill","doi":"10.1016/bs.apha.2026.05.003","DOIUrl":"10.1016/bs.apha.2026.05.003","url":null,"abstract":"<p><p>Chimeric antigen receptor (CAR) T cell therapy has fundamentally altered the treatment landscape for hematological malignancies, yet the autologous ex vivo manufacturing process that underpins commercially available products imposes severe constraints on access, scalability, and cost. In vivo CAR T cell generation can be achieved by direct systemic administration of gene delivery vehicles engineered to selectively transduce endogenous T lymphocytes. This approach reconceives the patient's own lymphoid organs as a bioreactor. Two major platforms are now entering clinical testing: engineered viral vectors that stably integrate a CAR transgene, and lipid nanoparticles (LNPs) that deliver CAR-encoding RNA for transient expression. This review examines the biological rationale, delivery engineering, immunological barriers, CAR payload design, early clinical evidence, and future directions of this field. Particular emphasis is placed on the pharmacological principles that distinguish in vivo from ex vivo approaches, and on the transformative potential for indications that lie beyond the current reach of conventional CAR T cell therapy.</p>","PeriodicalId":7366,"journal":{"name":"Advances in pharmacology","volume":"106 ","pages":"213-251"},"PeriodicalIF":0.0,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148395556","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Advances in pharmacologyPub Date : 2026-01-01Epub Date: 2026-05-27DOI: 10.1016/bs.apha.2026.05.004
Angela Z Gong, Mark A Sellmyer
{"title":"Tracking therapeutic T cells in vivo.","authors":"Angela Z Gong, Mark A Sellmyer","doi":"10.1016/bs.apha.2026.05.004","DOIUrl":"10.1016/bs.apha.2026.05.004","url":null,"abstract":"<p><p>Engineered cell therapies have shown remarkable promise in treating malignancies and autoimmune diseases. As of 2025, there are seven FDA-approved chimeric antigen receptor (CAR) T therapies, each treating different cancers. Despite rapid progress in developing new therapies, there is a lack of understanding about the in vivo behavior of adoptively transferred cells. Noninvasive methods that monitor CAR T cell dynamics and persistence in vivo are critical to both assess individual patients' responses to therapy in real time and to guiding improvements to engineered cell therapies. Imaging approaches that evaluate persistence, proliferation, functionality, and distribution of T cells will aid in optimizing therapeutic development and adjustment of treatment strategies in the clinic. Molecular imaging can noninvasively track labeled cells on a whole-body level and enable long-term monitoring of adoptively transferred cells in a manner compatible with the proliferation and persistence of therapeutic cells and may someday be able to bypass the need for paired biopsies. In this chapter, we highlight examples of cell tracking and labeling strategies for engineered T cell therapies.</p>","PeriodicalId":7366,"journal":{"name":"Advances in pharmacology","volume":"106 ","pages":"253-281"},"PeriodicalIF":0.0,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148395642","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Advances in pharmacologyPub Date : 2026-01-01Epub Date: 2026-10-08DOI: 10.1016/bs.apha.2026.08.008
Ariela Goldenshluger
{"title":"Follow up after metabolic bariatric surgery.","authors":"Ariela Goldenshluger","doi":"10.1016/bs.apha.2026.08.008","DOIUrl":"https://doi.org/10.1016/bs.apha.2026.08.008","url":null,"abstract":"<p><p>Metabolic and bariatric surgery (MBS) is the most effective treatment for severe obesity and obesity-related comorbidities; however, the profound anatomical, physiological, metabolic, and nutritional changes induced by surgery require lifelong postoperative monitoring. This chapter reviews the evidence-based framework for post-MBS care across both the early (0-6 months) and long-term (>6 months) postoperative periods. During the early postoperative phase, follow-up focuses on monitoring surgical complications, guiding dietary progression, initiating micronutrient supplementation, adjusting pharmacotherapy, and introducing physical activity. Key complications, including anastomotic leaks, strictures, marginal ulcers, and dumping syndrome, require timely identification and management. Micronutrient deficiencies, particularly iron, vitamin B12 and vitamin D, are common and require procedure-specific supplementation protocols. Long-term follow-up addresses nutritional status, weight maintenance, bone health, physical activity, psychological well-being, and management of obesity-related conditions. Weight recurrence, affecting approximately 20-30 % of patients, requires a stepwise approach incorporating behavioral, pharmacological, and revisional surgical strategies. Anti-obesity medications, particularly GLP-1 receptor agonists, play an important role in post-bariatric chronic disease management. Special populations, including pregnant women, require individualized monitoring and supplementation protocols. Lifelong multidisciplinary follow-up involving surgeons, dietitians, physicians, mental health professionals, primary care providers, and other specialists when needed is essential to optimize outcomes and prevent long-term complications. MBS should be viewed not as a standalone intervention, but as one component of lifelong obesity care.</p>","PeriodicalId":7366,"journal":{"name":"Advances in pharmacology","volume":"107 ","pages":"171-206"},"PeriodicalIF":0.0,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149317004","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Advances in pharmacologyPub Date : 2026-01-01Epub Date: 2026-05-25DOI: 10.1016/bs.apha.2026.05.007
Yudian Xiao, Mingliang Bai, Melgious Jin Yan Ang, Michael J Mitchell, Xuexiang Han
{"title":"Transient T cell therapies.","authors":"Yudian Xiao, Mingliang Bai, Melgious Jin Yan Ang, Michael J Mitchell, Xuexiang Han","doi":"10.1016/bs.apha.2026.05.007","DOIUrl":"https://doi.org/10.1016/bs.apha.2026.05.007","url":null,"abstract":"<p><p>Chimeric antigen receptor (CAR) T cell therapy has achieved clinical success in hematological malignancies, but its reliance on viral vectors and complex ex vivo manufacturing poses challenges related to safety, cost, and scalability. Next-generation strategies, including universal (\"off-the-shelf\") and in vivo CAR-T cell therapies, have emerged to address these limitations. The latter strategy employs targeted delivery systems to directly program patients' T cells in situ, bypassing ex vivo manipulation and offering a more streamlined, scalable, and safer therapeutic paradigm. The success of in vivo CAR-T cell therapy relies on targeted delivery systems. While engineered lentiviruses enable stable integration, non-viral vectors for transient CAR expression offer superior pharmacological control. This approach, exemplified by lipid nanoparticles in combination with mRNA, avoids risks of insertional mutagenesis and enables titratable, short-lived CAR expression, thereby enhancing safety management and suitability for applications beyond oncology. In this chapter, we first delineate the pharmacological imperative for transient CAR expression. Next, various delivery strategies are systematically reviewed, including ex vivo electroporation, in vivo non-viral systems, and engineered virus-like particles. Afterwards, we summarize the ongoing clinical trials of transient CAR-T cell therapy for oncology and non-oncology indications. Finally, we provide perspectives on the development of next-generation transient CAR-T cell therapies.</p>","PeriodicalId":7366,"journal":{"name":"Advances in pharmacology","volume":"106 ","pages":"179-212"},"PeriodicalIF":0.0,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148395657","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Advances in pharmacologyPub Date : 2026-01-01Epub Date: 2026-09-06DOI: 10.1016/bs.apha.2026.06.004
Rajiev Hallock, Peminda Cabandugama, Niki Patel
{"title":"Digital health, technology, AI, and wearables in obesity care.","authors":"Rajiev Hallock, Peminda Cabandugama, Niki Patel","doi":"10.1016/bs.apha.2026.06.004","DOIUrl":"https://doi.org/10.1016/bs.apha.2026.06.004","url":null,"abstract":"<p><p>Digital health technologies, including mobile health (mHealth) applications, text messaging (SMS), telehealth, artificial intelligence (AI), and wearable devices, are increasingly integrated into obesity prevention, treatment and long-term management. This chapter reviews the current evidence for each modality. Mobility health apps produce modest but statistically significant weight reductions over controls, with peak efffectiveness at 3-6 months, though long-term sustainability beyong 12 months remains limited. SMS-based behavioral interventions, yield small to moderate weight loss, particularly when combined with health coaching. Telehealth has demonstated non-inferiority to in-person care for both behavioral weight management and obesity pharmacotherapy, with comparable or superior rates of clinically meaningful weight loss. AI technologies, encompassing machine learning, deep learning and large language models, show promise in predictive modeling, personalized digital therapeutics, and automated food recognition, with emerging trial evidence supporting non-inferiority to human-led coaching programs. Wearable devices contribute modest weight reduction and increased physical activity, with greatest benefit observed in interventions lasting>12 weeks and in middle-aged or older adults with chronic diseases. Multicomponent digital interventions lasting ≥12 weeks and in middle-aged or older adults with chronic diseases. Multicomponent digital interventions combining patient education, promoting self-monitoring and a qualified interventionist produce the largest and post sustained effects.Key implementation challenges include digital divide, engagement and adherence barriers, interventions heterogeneity between programs, limited safety reporting, cultural and linguistic differences, and the need for equitable access across diverse populations. Optimal interventions incorporate ≥8 behavior change techniques, combine diet and physical activty components, and span 6-12 months with extended contact for maintenance.</p>","PeriodicalId":7366,"journal":{"name":"Advances in pharmacology","volume":"107 ","pages":"231-251"},"PeriodicalIF":0.0,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149317065","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Advances in pharmacologyPub Date : 2026-01-01Epub Date: 2026-02-25DOI: 10.1016/bs.apha.2026.02.003
Cristina Díaz-Perlas
{"title":"Chemically enhanced brain shuttle peptides.","authors":"Cristina Díaz-Perlas","doi":"10.1016/bs.apha.2026.02.003","DOIUrl":"10.1016/bs.apha.2026.02.003","url":null,"abstract":"<p><p>The blood-brain barrier (BBB) constitutes a major impediment to central nervous system pharmacotherapy due to its highly selective permeability and enzymatic defense mechanisms. Brain shuttle peptides have emerged as a promising modality for overcoming this barrier, primarily via receptor-mediated transcytosis. To enhance their pharmacokinetic properties and transcytosis efficiency, several structural and chemical optimization strategies have been employed. Cyclization and retro-enantio modifications confer proteolytic resistance while preserving receptor affinity, as demonstrated by engineered peptides such as retro-D-THR, retro-D-T7, and BB4. Venom-derived scaffolds, including MiniAp-4 and MiniCTX3, further exemplify the potential of naturally occurring peptides for BBB penetration. Multivalent presentation, achieved through branched architectures or nanoparticle surface functionalization, significantly increases avidity and cellular uptake, thereby improving transcytosis. Dual-ligand systems, such as THR-TAT conjugates, have shown synergistic effects in glioma models, enhancing both BBB crossing and tumor targeting. While PEGylation is widely utilized in drug delivery to prolong circulation and reduce immunogenicity, its application in brain shuttle systems remains limited due to potential interference with receptor-mediated uptake. Collectively, these advances underscore the versatility of protease-resssistant brain shuttle peptides as targeted delivery vehicles for CNS therapeutics and provide a strong foundation for their translation into clinical applications.</p>","PeriodicalId":7366,"journal":{"name":"Advances in pharmacology","volume":"105 ","pages":"133-170"},"PeriodicalIF":0.0,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148196888","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Advances in pharmacologyPub Date : 2026-01-01Epub Date: 2026-03-09DOI: 10.1016/bs.apha.2026.02.001
Alexander M Ille, Fenny H F Tang, Ethan R Chen, Wadih Arap, Renata Pasqualini
{"title":"Brain shuttle peptides derived from phage display.","authors":"Alexander M Ille, Fenny H F Tang, Ethan R Chen, Wadih Arap, Renata Pasqualini","doi":"10.1016/bs.apha.2026.02.001","DOIUrl":"10.1016/bs.apha.2026.02.001","url":null,"abstract":"<p><p>Vascular beds within different tissues, including the brain, exhibit diverse molecular heterogeneity. Screening of peptide libraries using in vivo phage display exploits this heterogeneity, enabling the discovery of peptide ligands which selectively home to specific tissues. A prime example is identification of the iron-mimicking peptide CRTIGPSVC which undergoes receptor-mediated transport across the blood-brain barrier (BBB) by binding to the transferrin/transferrin receptor (TfR) complex. Various other brain-homing and BBB-crossing peptides have been discovered by in vivo phage display as well as phage display performed in vitro, i.e., in BBB models, cultured cells, and immobilized receptors. Furthermore, these peptides have been used for preclinical therapeutic applications for a number of different brain disorders. Continued research involving phage display is expected to further characterize the determinants of BBB transport, uncover additional BBB-crossing peptides, and facilitate ongoing development of brain-targeted therapies.</p>","PeriodicalId":7366,"journal":{"name":"Advances in pharmacology","volume":"105 ","pages":"83-97"},"PeriodicalIF":0.0,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148196898","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Advances in pharmacologyPub Date : 2026-01-01Epub Date: 2026-03-14DOI: 10.1016/bs.apha.2026.02.002
Nikolina Mohović, Marko Njirjak, Ena Dražić, Patrizia Janković Bevandić, Daniela Kalafatovic
{"title":"Brain shuttle peptides: From permeability assay toolbox to data-driven discovery.","authors":"Nikolina Mohović, Marko Njirjak, Ena Dražić, Patrizia Janković Bevandić, Daniela Kalafatovic","doi":"10.1016/bs.apha.2026.02.002","DOIUrl":"10.1016/bs.apha.2026.02.002","url":null,"abstract":"<p><p>The blood-brain barrier (BBB) is a highly selective transport interface that protects the central nervous system (CNS), but its complex cellular and molecular architecture presents a major challenge for drug delivery to the brain. Peptides have emerged as promising brain shuttles due to their selectivity, ease of synthesis, and ability to engage endogenous transport mechanisms such as receptor- or adsorptive-mediated transcytosis. We provide an overview of in vitro and in vivo models, ranging from artificial membranes, dynamic BBB-on-a-chip systems and mass-based quantification techniques to brain perfusion and molecular imaging. Particular emphasis is placed on how these approaches are selected and combined to assess BBB permeability, transport mechanisms, and brain distribution of peptide shuttles. Recently, machine learning methods have been increasingly used to identify peptide sequences with BBB-crossing potential. By highlighting recent examples and key methodological considerations, this chapter aims to guide researchers in selecting appropriate tools and strategies for studying peptide transport across the BBB.</p>","PeriodicalId":7366,"journal":{"name":"Advances in pharmacology","volume":"105 ","pages":"99-131"},"PeriodicalIF":0.0,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148196967","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Advances in pharmacologyPub Date : 2026-01-01Epub Date: 2026-05-21DOI: 10.1016/bs.apha.2026.05.006
Monika Holubová, Valentina Sofia Caputo Galarce, Miroslava Čedíková
{"title":"T Cell subsets for therapy-unconventional CD1d-restricted natural killer T cells.","authors":"Monika Holubová, Valentina Sofia Caputo Galarce, Miroslava Čedíková","doi":"10.1016/bs.apha.2026.05.006","DOIUrl":"https://doi.org/10.1016/bs.apha.2026.05.006","url":null,"abstract":"<p><p>Unconventional T cells, including gamma delta (γδ) T cells, mucosal-associated invariant T (MAIT) cells, and CD1d-restricted natural killer T (NKT) cells, comprise a unique component of the immune system. These cells play critical roles in host defense, immune regulation, and disease pathogenesis. In particular, invariant NKT (iNKT) cells have emerged as key immunological orchestrators that bridge innate and adaptive immunity by rapidly recognizing lipid antigens presented by CD1d molecules. This chapter provides a comprehensive overview of iNKT cell biology, including their development, phenotypic and functional heterogeneity, and activation mechanisms. It discusses the role of iNKT cells in pathological conditions in detail. Their ability to directly kill tumor cells, as well as their potential to orchestrate the immune response, opens up new possibilities for anti-cancer therapy. Their contribution to immune response regulation and tolerance highlights their critical role in infectious diseases and transplantation. The chapter summarizes current clinical approaches aimed at harnessing iNKT cells, including in vivo activation strategies, adoptive transfer of ex vivo-expanded cells, and developing chimeric antigen receptor (CAR)-engineered iNKT cells. These emerging therapies have advantages over conventional CAR-T approaches, such as reduced toxicity and the potential for allogeneic use. Finally, the chapter discusses the role of type II NKT cells and their cross-regulatory interactions with iNKT cells. Overall, CD1d-restricted NKT cells are a promising target for next-generation immunotherapies. However, further mechanistic and clinical studies are needed to realize their full therapeutic potential.</p>","PeriodicalId":7366,"journal":{"name":"Advances in pharmacology","volume":"106 ","pages":"65-99"},"PeriodicalIF":0.0,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148395554","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Preface.","authors":"","doi":"10.1016/S1054-3589(26)00065-7","DOIUrl":"https://doi.org/10.1016/S1054-3589(26)00065-7","url":null,"abstract":"","PeriodicalId":7366,"journal":{"name":"Advances in pharmacology","volume":"106 ","pages":"xv-xvi"},"PeriodicalIF":0.0,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148395593","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}